The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 38 | — | 20.1x | Near average | |
Growth | 3 | — | 5.6% | Below average | |
Quality | 50 | 487.7% | 7.6% | Near average | |
Safety | 44 | 0.8x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | 95 | — | — | Above average | |
Sentiment | 48 | — | — | Near average |
LeonaBio, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy LeonaBio, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
LONA stock has witnessed a positive shift in the average target price over the past thirty days, with the consensus rising by 50% from $10 to $15. This momentum is driven by recent coverage from major institutions such as Piper Sandler and Cantor Fitzgerald with an 'Overweight' rating, reflecting optimism despite the absence of current revenue and expectations of continued losses in earnings per share (EPS) until the end of 2025.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.